Mike Putman

@EBRheum

Rheumatologist. & enthusiast. Currently at Northwestern. Founder of the Evidence Based Rheumatology Podcast. Co-host of Rheum4Debate.

Vrijeme pridruživanja: siječanj 2018.

Tweetovi

Blokirali ste korisnika/cu @EBRheum

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @EBRheum

  1. Prikvačeni tweet
    17. sij

    Rheum4Debate Ep.4 at ! and debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line" Vote the poll AFTER you listen! Whoever gains the most votes is declared the winner

    Poništi
  2. 30. sij

    Timely case series of 41 pts w/the 2019 novel coronavirus, PMID: 31986264 1. Fever ubiquitous 2. Flu like symptoms common 3. Respiratory sx seem to drive outcomes Selection bias (hospitalized cohort) likely inflated mortality (15%); rate in all comers probably <5%

    Poništi
  3. 26. sij

    Really nice editorial re:complications from therapy in ANCA-associated vasculitis Encouraging to note progress - previously 93% 2-year mortality! Comes at a price - 1/4 of patients develop infxn, typically early in tx course, and infxn #1 cause mortality Much still to do!

    Poništi
  4. 26. sij

    NEW EULAR guidelines for RA, PMID 31969328 1. TtT! 🙏 2. MTX 1st line 🥰 3. More csDMARDs if no poor prognostic factors 🙄 4. Add bDMARD/JAKi if poor prognostic factors & csDMARD failure 🙂 5. IL6/JAKi if csDMARD not possible 👍 Overall good. I try HCQ but typically skip #3

    Poništi
  5. 25. sij

    You probably also follow and already heard (), but still: 1. Insightful thoughts about spending your time (improve yourself, address worthy problems) 2. Re:medical writers - “There is a simple rule.. you write papers... write it yourself”

    Poništi
  6. 23. sij

    NEW podcast, anifrolumab for SLE. I cover TULIP-1 and TULIP-2 Interesting ?s, including multiple hypothesis testing, surrogate endpoints, and PROs. Let me know what you think after listening; share with friends! Subscribe at

    Poništi
  7. 23. sij

    NEW 2020 BSR Guidelines for GCA 1. Thoughtful algorithm for dx! 2. Long (12-18 mo) taper rec but allows for MTX/TCZ to shorten 3. Strong “can consider” TCZ; conditional “might consider” MTX Congrats !

    Poništi
  8. 19. sij

    TAKT RCT of TCZ vs PLBO in takayasu arteritis, 96wk open label extension just published PMID 31951279 Good GC taper/sparing, 86% improved imaging, & clinically important PROs met Can’t trust open label data; this is essentially a well funded cohort study. Still, nice to see!

    Poništi
  9. 19. sij

    VITAMINS RCT published in , open label VitC & thiamine vs none in septic shock, PMID: 31950979 Intervention aside, is hydrocortisone q6hrs standard of care now? I thought ADRENAL was a negative study

    Poništi
  10. proslijedio/la je Tweet
    15. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    Support public funding for research. Donate to the Rheumatology Research Foundation

    Poništi
  11. 15. sij

    Curious to hear what people think: “Pharmaceutical companies should be able to fund, help write, and approve the final draft of clinical practice guidelines”

    Prikaži ovu nit
    Poništi
  12. 15. sij

    NEW Guidelines for SSc-ILD 1. HRCT at dx 🙂 2. Lovely flowchart! 👍 3. Nintedanib gets its own table? 🧐 4. FUNDED by PHARMA? 😡 5. WRITING HELP from PHARMA? 🤯 Apparently practice guidelines are now paid for and co-authored by pharma...

    Prikaži ovu nit
    Poništi
  13. 14. sij

    2020 Medscape Physician Survey: Per usual, rheum did well w/number needed to specialize (NNS) ~ 8 vs less happy ones ;) Lots of selection bias, responder bias, etc but I’ll admit I looked at this when choosing a path! Thanks for the poll!

    Poništi
  14. proslijedio/la je Tweet
    8. sij

    Rheum4Debate is back! and will debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line" Vote the pre-debate poll NOW to have you voice heard! Podcast lands next Thursday :)

    Poništi
  15. 8. sij

    Rheum4Debate is back! and will debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line" Vote the pre-debate poll NOW to have you voice heard! Podcast lands next Thursday :)

    Poništi
  16. 8. sij

    Thoroughly enjoyed on DAGs in recent podcast Reminded me of my favorite one of all time, where managed to fit the entirety of nutritional epi into one DAG

    Poništi
  17. 7. sij

    2020 ACR Guidelines for OA in A&R this week Generally recommend: exercise, wt loss, CMC orthosis, NSAIDS, CSI Strongly against: TENS, glucosamine, chondroitin, PRP, stem cells, all DMARDS NGFi (promising?) and chiro (less so) missed the party Nice job et al!

    Poništi
  18. 6. sij

    Fun to hear an old favorite () put out a podcast with a new favorite () Listen to both and checkout the Casual Inference podcast!!

    Poništi
  19. 6. sij

    2013 RACAT, triple tx vs TNF in MTX resistant RA, PMID 23755969 Typically interpreted "Triple Tx and TNF have equal efficacy" Re-read recently & noted significant differences favoring ETN for remission: DAS28<2.6 (NNT~11) & ACR70 (NNT~9) Wondering if we have this right...

    Poništi
  20. 5. sij

    Someone’s mother has four sons. North, South and East. What is the name of the fourth son. Private message me the name of the fourth son. If you lose, you have to repost. I lost to

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·